FDA Grants Early Approval To Daraxonrasib Pancreatic Cancer Drug With Survival Benefit
The FDA granted expedited approval Wednesday, Aug. 26, 2026, to daraxonrasib, marketed as Rasonque, for advanced metastatic pancreatic cancer, clearing a new option for patients whose disease no longer responds to other treatments.[1]
In a 500-patient randomized Phase 3 trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, and fewer severe side effects were reported.[1] Revolution Medicines will sell the drug as Rasonque, and the company set a U.S. list price of about $39,800 for a one-month supply.[1] Common side effects include skin rash, mouth sores and diarrhea.[1] FDA acting commissioner Kyle Diamantas said the agency approved the drug more than six months ahead of its target date and called doing so part of the FDA's "fundamental duty" to deliver treatments quickly.[1]
Revolution Medicines acquired Warp Drive Bio in 2018 and developed daraxonrasib as an oral pan-RAS(ON) tri-complex inhibitor, entering first-in-human trials in 2022. The drug earned Breakthrough Therapy and Orphan Drug designations and produced the positive RASolute 302 Phase 3 results announced in April 2026 that formed the basis for approval. Earlier public interest, including former Sen. Ben Sasse describing his use of daraxonrasib on CBS's 60 Minutes, prompted expanded access programs before approval.[1]
Initial coverage celebrated the survival gains as a landmark step against RAS mutations once seen as undruggable.[1] Later reporting shifted attention to affordability after coverage cited the roughly $39,800-per-month list price and patients and clinicians raised access concerns in CBS News segments.[2] An estimated 67,530 Americans will be diagnosed with pancreatic cancer in 2026, and five-year relative survival for distant-stage disease is about 3%, underscoring the stakes for new treatments.
The mainstream summary highlights the survival benefit of daraxonrasib but does not address the broader context of economic inequality in accessing such treatments. A 2024 analysis in Nature Reviews Clinical Oncology points out that high launch prices for anticancer therapies, like the $39,800 monthly cost of Rasonque, are often set as high as the market will bear due to the lack of price negotiation in the U.S. This results in prices that are 2-3 times higher than those in peer countries, which can severely limit access for lower-income patients and increase the risks of non-adherence and mortality.
Additionally, while the summary mentions the estimated 67,530 new pancreatic cancer diagnoses in 2026, it does not emphasize the staggering 52,740 projected deaths from the disease, nor does it highlight the 5-year relative survival rate of just 3% for distant-stage pancreatic cancer. These statistics underscore the critical need for effective treatments like daraxonrasib but also raise urgent questions about affordability and access in a healthcare system that often prioritizes profit over patient care.[3][4]
Show source details & analysis (4 sources)
📊 Relevant Data
An estimated 67,530 people in the United States will be diagnosed with pancreatic cancer in 2026, with 52,740 projected deaths from the disease.
Cancer Facts & Figures 2026 — American Cancer Society
The 5-year relative survival rate for distant-stage (metastatic) pancreatic cancer is 3%, compared with 13% across all stages combined.
Survival Rates for Pancreatic Cancer — American Cancer Society
📌 Key Facts
- The FDA granted expedited approval on Wednesday, August 26, 2026 to daraxonrasib (brand name Rasonque) for advanced metastatic pancreatic cancer, clearing the drug for patients who have run out of other options (daraxonrasib (Rasonque)).
- Phase 3 results from a 500‑patient randomized study showed median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, with fewer severe side effects reported (Phase 3 results).
- The U.S. list price was reported at about $39,800 for a one‑month supply, and coverage noted that cost could be a major barrier for patients despite the survival benefit (one‑month supply).
- Revolution Medicines will market the drug as Rasonque, and key side effects described include skin rash, mouth sores, diarrhea and other digestive issues (Rasonque).
- FDA acting commissioner Kyle Diamantas said the agency approved the drug more than six months ahead of its target date, calling the step part of the FDA's "fundamental duty" to deliver treatments quickly (Kyle Diamantas).
- Earlier public interest and high‑profile attention — including former Sen. Ben Sasse describing his use of the drug on CBS's '60 Minutes' — prompted FDA authorization of expanded access programs before full approval (Ben Sasse).
- CBS aired video segments on Wednesday, August 26, 2026 at 6:55 PM Central and Thursday, August 27, 2026 at 8:55 AM Central that explained what the approval could mean for late‑stage patients and emphasized affordability concerns and public reaction to the roughly $39,800‑per‑month list price (CBS segment).
📰 Source Timeline (4)
Follow how coverage of this story developed over time
- The CBS segment, aired at 8:55 a.m. Central on Thursday, August 27, 2026, focuses on concerns about the affordability of daraxonrasib (Rasonque) following its FDA approval, highlighting patient and public reaction to the roughly $39,800-per-month list price.
- The piece frames the pill specifically as a "new pill that can treat pancreatic cancer" and emphasizes cost as a central barrier for patients, beyond the clinical survival benefit already reported.
- Article confirms the FDA granted expedited approval to daraxonrasib (brand name Rasonque) for advanced metastatic pancreatic cancer on Wednesday, August 26, 2026.
- NPR specifies the U.S. list price as approximately $39,800 for a one-month supply, lower than the roughly $477,000-per-year figure cited earlier but still very high.
- The article reiterates Phase 3 survival results: in a 500-patient randomized study of metastatic disease that had stopped responding to prior treatment, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, with fewer severe side effects.
- FDA acting commissioner Kyle Diamantas is quoted saying the agency approved the drug more than six months ahead of its target date and framed doing so as part of the FDA's "fundamental duty" to deliver treatments quickly.
- The story notes the drug will be sold by Revolution Medicines under the brand name Rasonque and describes key side effects (skin rash, mouth sores, diarrhea and other digestive issues).
- NPR adds that earlier public interest, including former Sen. Ben Sasse describing his use of the drug on CBS's "60 Minutes," led FDA to authorize expanded access before approval.
- Clinicians quoted describe the approval as "one of the most anticipated" in pancreatic cancer and highlight that the agent effectively targets KRAS/RAS mutations previously considered "undruggable."
- CBS News aired a video segment on August 26, 2026, in which medical correspondent Dr. Céline Gounder explained what the FDA approval of the new pancreatic cancer drug could mean for late-stage patients.
- The segment emphasizes that the newly approved drug "could extend the life" of patients with late-stage pancreatic cancer, translating the clinical-trial survival data into expected patient impact for a general audience.
- The article does not add new numerical trial data or regulatory details beyond those already reported, instead focusing on expert interpretation and implications for patient care.